We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Abzena | LSE:ABZA | London | Ordinary Share | GB00BN65QN46 | ORD GBP0.002 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 15.75 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMABZA
Abzena PLC
31 August 2017
Hardman Research: Accelerating towards profitability
Accelerating towards profitability: Abzena is a global life sciences group offering a broad range of integrated services and technologies to enable the development of better biopharmaceutical drugs. With strong footprints in both the US and UK, the company provides a fee-for-service offering with the opportunity of embedding its technology - 'Abzena Inside' - into commercial products, on which it will derive a long-term royalty stream. Fiscal 2017 represented a period of integration and growth, now the focus is on accelerating the growth opportunity towards profitability. Meanwhile, Abzena is continuing to attract licensing partners as evidenced by two further deals recently.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/abzena-plc-documents/31.08.17-accelerating-towards-profitability.pdf
To contact us: Analysts: Hardman & Co Dr Martin Hall mh@hardmanandco.com 35 New Broad Street Dr Dorothea Hill dmh@hardmanandco.com London Dr Gregoire Pave gp@hardmanabdco.com EC2M 1NH Telephone: +44 20 7194 7622 Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPBMBTMBMJBPR
(END) Dow Jones Newswires
August 31, 2017 07:15 ET (11:15 GMT)
1 Year Abzena Chart |
1 Month Abzena Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions